↓ Skip to main content

Dove Medical Press

Article Metrics

Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first- episode or multi-episode schizophrenia

Overview of attention for article published in Neuropsychiatric Disease and Treatment, June 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page
googleplus
1 Google+ user

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
27 Mendeley
Title
Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first- episode or multi-episode schizophrenia
Published in
Neuropsychiatric Disease and Treatment, June 2013
DOI 10.2147/ndt.s45697
Pubmed ID
Authors

Kenji Washida, Aoki, Habara, Sato, Oka, Takeda, Yosimura, Tanaka

Abstract

The aim of this study was to examine the speed of response, doses, and safety of treatment with second-generation antipsychotics (SGAs) in patients at ultra-high risk (UHR) compared to those with schizophrenia.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 4%
Unknown 26 96%

Demographic breakdown

Readers by professional status Count As %
Other 5 19%
Student > Ph. D. Student 4 15%
Student > Master 4 15%
Researcher 4 15%
Student > Bachelor 3 11%
Other 4 15%
Unknown 3 11%
Readers by discipline Count As %
Medicine and Dentistry 10 37%
Psychology 8 30%
Biochemistry, Genetics and Molecular Biology 1 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Veterinary Science and Veterinary Medicine 1 4%
Other 0 0%
Unknown 6 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 July 2013.
All research outputs
#8,379,338
of 14,535,828 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,181
of 2,442 outputs
Outputs of similar age
#73,197
of 154,516 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#31
of 65 outputs
Altmetric has tracked 14,535,828 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,442 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 154,516 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.